Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual

May 23, 2024

https://www.globenewswire.com/news-release/2024/05/23/2887702/0/en/Compass-Therapeutics-to-Present-Phase-1-Data-for-CTX-471-A-Novel-CD137-Agonist-Antibody-Demonstrating-Anti-Tumor-Activity-in-Patients-Who-Have-Progressed-on-Approved-PD-1-or-PD-L1-.html

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.